Actos
Actos is a new class of diabetes drug which increases the bodies sensitivity to insulin. It can be referred to as both a hiazolidinedione or glitazone. The drug was approved by the FDA in 1999 and is manufactured by Takeda Chemical Industries.
The first drug of its class, Rezulin, was taken off the market in 2000 shortly after its initial release due to a number of liver failures and related disease. The American Heart Association and American Diabetes Association have given directives on how to use the drug in order to minimize heart damage and diabetes complications. Some diabetics who use the drug see an increase in the severity of their symptoms.
A study published in September of 2003 indicated a total of six congenitive heart failures resulting in people taking either pioglitazone (Actos) or rosiglitazone (Avandia). All six patients complained of shortness of breath, swollen feet, and weight gain, all of which are symptoms of congestive heart failure and pulmonary edema, or the buildup of fluid in the lungs.
Four of the six people in this study also had chronic renal insufficiency, meaning their kidneys no longer functioned correctly. Only two had any previous signs of heart disease. Each had used the diabetes medications for between one and sixteen months. Three of the patients exhibited symptoms within one to three months after the dose of their diabetes drug had been increased.
If you or a loved one has suffered an injury, illness or death, that seems to have been someone else’s fault, call VanDerGinst Law at 1-866-843-7367 or click here for a FREE online case evaluation. The initial consultation is free of charge. If we agree to handle your injury case, we will work on a contingency fee basis, which means we get paid for our services only if, and when, there is a money recovery for you. In many cases a lawsuit must be filed before an applicable expiration date, known as a statute of limitations. So please call right away to ensure that you do not waive your right to possible compensation.
Links on the Web
